Calcified Tissue International

, Volume 89, Issue 2, pp 130–139

Teriparatide in Bisphosphonate-Resistant Osteoporosis: Microarchitectural Changes and Clinical Results After 6 and 18 months

  • B. Jobke
  • B. Muche
  • A. J. Burghardt
  • J. Semler
  • T. M. Link
  • S. Majumdar
Original Research

Abstract

A number of osteoporotic patients under bisphosphonate treatment present persistent fragility fractures and bone loss despite good compliance. The objective of this 18-month prospective study was to investigate the effect of teriparatide [rhPTH(1–34)] in 25 female osteoporotics who were inadequate responders to oral bisphosphonates and to correlate microarchitectural changes in three consecutive iliac crest biopsies measured by micro-computed tomography (μCT) with bone mineral density (BMD) and bone serum markers. Scanned biopsies at baseline (M0), 6 months (M6), and 18 months (M18) demonstrated early significant (P < 0.01) increases in bone volume per tissue volume (+34%) and trabecular number (+14%) at M6 with only moderate changes in most μCT structural parameters between M6 and M18. μCT-measured bone tissue density was significantly decreased at M18, expressing an overall lower degree of tissue mineralization characteristic for new bone formation despite unchanged trabecular thickness due to increased intratrabecular tunneling at M18. μCT results were consistent with serum bone turnover markers, reaching maximal levels of bone alkaline phosphatase and serum β-crosslaps at M6, with subsequent decline until M18. BMD assessed by DXA demonstrated persistent increases at the lumbar spine until M12, whereas no significant change was observed at the hip. Type (alendronate/risedronate) and duration (3.5 ± 4 years) of prior bisphosphonate treatment did not influence outcome on μCT, BMD, or bone marker results. The overall results indicate a positive ceiling effect of teriparatide on bone microarchitecture and bone markers after 6 and 12 months for lumbar spine BMD, with no additional gain until M18 in bisphosphonate nonresponders.

Keywords

μCT Teriparatide Biopsy Tissue mineralization Histology 

References

  1. 1.
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRefGoogle Scholar
  2. 2.
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRefGoogle Scholar
  3. 3.
    Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736–746PubMedCrossRefGoogle Scholar
  4. 4.
    Eriksen EF, Melsen F, Sod E, Barton I, Chines A (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620–625PubMedCrossRefGoogle Scholar
  5. 5.
    Jobke B, Kulle B, Semler J, Delling G (2006) Bisphosphonates improve bone microarchitecture in middle-aged males with osteoporosis by reducing bone turnover: a paired biopsy micro-CT analysis over 38 months. J Bone Miner Res 21(Suppl 1)Google Scholar
  6. 6.
    Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J et al (2007) Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int 18:973–979PubMedCrossRefGoogle Scholar
  7. 7.
    Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R et al (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244–1253PubMedCrossRefGoogle Scholar
  8. 8.
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941PubMedCrossRefGoogle Scholar
  9. 9.
    McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M et al (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768PubMedCrossRefGoogle Scholar
  10. 10.
    Chen P, Jerome CP, Burr DB, Turner CH, Ma YL, Rana A et al (2007) Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide. J Bone Miner Res 22:841–848PubMedCrossRefGoogle Scholar
  11. 11.
    Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751PubMedCrossRefGoogle Scholar
  12. 12.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM et al (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970PubMedCrossRefGoogle Scholar
  13. 13.
    Dobnig H (2004) A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin Pharmacother 5:1153–1162PubMedCrossRefGoogle Scholar
  14. 14.
    Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC et al (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970–3977PubMedCrossRefGoogle Scholar
  15. 15.
    Jiang Y, Zhao J, Liao EY, Dai RC, Wu XP, Genant HK (2005) Application of micro-CT assessment of 3-D bone microstructure in preclinical and clinical studies. J Bone Miner Metab 23(Suppl):122–131PubMedCrossRefGoogle Scholar
  16. 16.
    Jobke B, Pfeifer M, Minne HW (2009) Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest. Connect Tissue Res 50:46–54PubMedCrossRefGoogle Scholar
  17. 17.
    Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600PubMedCrossRefGoogle Scholar
  18. 18.
    Moore RJ, Durbridge TC, Woods AE, Vernon-Roberts B (1989) Variation in histomorphometric estimates across different sites of the iliac crest. J Clin Pathol 42:814–816PubMedCrossRefGoogle Scholar
  19. 19.
    Delling G, Dreyer T, Hahn M, Vogel M, Rittinghaus EF, Hesch RD (1990) Morphologic study of iliac crest spongiosa in patients with osteoporosis treated according to the ADFR (activation, depression of resorption, formation, repeat the cycle) with parathyroid hormone and diphosphonates (Hannover PTH I study) [in German]. Z Orthop Ihre Grenzgeb 128:1–5PubMedCrossRefGoogle Scholar
  20. 20.
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L et al (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853PubMedCrossRefGoogle Scholar
  21. 21.
    Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P et al (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156PubMedCrossRefGoogle Scholar
  22. 22.
    Paschalis EP, Glass EV, Donley DW, Eriksen EF (2005) Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. J Clin Endocrinol Metab 90:4644–4649PubMedCrossRefGoogle Scholar
  23. 23.
    Engelke K, Karolczak M, Lutz A, Seibert U, Schaller S, Kalender W (1999) Micro-CT. Technology and application for assessing bone structure. Radiologe 39:203–212PubMedCrossRefGoogle Scholar
  24. 24.
    Hahn M, Vogel M, Pompesius-Kempa M, Delling G (1992) Trabecular bone pattern factor—a new parameter for simple quantification of bone microarchitecture. Bone 13:327–330PubMedCrossRefGoogle Scholar
  25. 25.
    Hildebrand T, Ruegsegger P (1997) Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Eng 1:15–23CrossRefGoogle Scholar
  26. 26.
    Muller R, Ruegsegger P (1997) Micro-tomographic imaging for the nondestructive evaluation of trabecular bone architecture. Stud Health Technol Inform 40:61–79PubMedGoogle Scholar
  27. 27.
    Ruegsegger P, Koller B, Muller R (1996) A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 58:24–29PubMedCrossRefGoogle Scholar
  28. 28.
    Burghardt AJ, Kazakia GJ, Laib A, Majumdar S (2008) Quantitative assessment of bone tissue mineralization with polychromatic micro-computed tomography. Calcif Tissue Int 83:129–138PubMedCrossRefGoogle Scholar
  29. 29.
    Kazakia GJ, Burghardt AJ, Cheung S, Majumdar S (2008) Assessment of bone tissue mineralization by conventional X-ray microcomputed tomography: comparison with synchrotron radiation microcomputed tomography and ash measurements. Med Phys 35:3170–3179PubMedCrossRefGoogle Scholar
  30. 30.
    Cosman F (2006) Anabolic therapy for osteoporosis: parathyroid hormone. Curr Rheumatol Rep 8:63–69PubMedCrossRefGoogle Scholar
  31. 31.
    Graeff C, Timm W, Nickelsen TN, Farrerons J, Marin F, Barker C et al (2007) Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 22:1426–1433PubMedCrossRefGoogle Scholar
  32. 32.
    Jakob F, Marin F, Martin-Mola E, Torgerson D, Fardellone P, Adami S et al (2006) Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the observational study of severe osteoporosis (OSSO). QJM 99:531–543PubMedCrossRefGoogle Scholar
  33. 33.
    Lewiecki EM (2003) Nonresponders to osteoporosis therapy. J Clin Densitom 6:307–314PubMedCrossRefGoogle Scholar
  34. 34.
    Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785–3793PubMedCrossRefGoogle Scholar
  35. 35.
    Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA et al (2009) Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1–84. Bone 44:113–119PubMedCrossRefGoogle Scholar
  36. 36.
    Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I et al (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173–1180PubMedCrossRefGoogle Scholar
  37. 37.
    Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T et al (2010) Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone 46:41–48PubMedCrossRefGoogle Scholar
  38. 38.
    Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN et al (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24:1672–1680PubMedCrossRefGoogle Scholar
  39. 39.
    Misof BM, Paschalis EP, Zoehrer R, Blouin S, Fratzl-Zelman N, Phipps R et al (2009) Effects of one year daily teriparatide treatment on iliac bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women treated prior with alendronate or risedronate. Bone 44:S425–S426CrossRefGoogle Scholar
  40. 40.
    Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2007) Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495–502PubMedCrossRefGoogle Scholar
  41. 41.
    de Vernejoul MC, Kuntz D, Miravet L, Goutallier D, Ryckewaert A (1981) Bone histomorphometric reproducibility in normal patients. Calcif Tissue Int 33:369–374PubMedCrossRefGoogle Scholar
  42. 42.
    Parisien MV, McMahon D, Pushparaj N, Dempster DW (1988) Trabecular architecture in iliac crest bone biopsies: infra-individual variability in structural parameters and changes with age. Bone 9:289–295PubMedCrossRefGoogle Scholar
  43. 43.
    Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X et al (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372PubMedCrossRefGoogle Scholar
  44. 44.
    Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK et al (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299PubMedCrossRefGoogle Scholar
  45. 45.
    Fuchs RK, Phipps RJ, Burr DB (2008) Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res 23:1689–1697PubMedCrossRefGoogle Scholar
  46. 46.
    Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. Osteoporos Int 15:992–997PubMedCrossRefGoogle Scholar
  47. 47.
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T et al (2005) One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • B. Jobke
    • 1
    • 3
  • B. Muche
    • 2
  • A. J. Burghardt
    • 1
  • J. Semler
    • 2
  • T. M. Link
    • 1
  • S. Majumdar
    • 1
  1. 1.Department of Radiology and Biomedical Imaging, Musculoskeletal and Quantitative Imaging Research GroupUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Department of OsteologyImmanuel-Hospital and Rheumaklinik Berlin-BuchBerlinGermany
  3. 3.Department of RadiologyHelios Klinikum Berlin-BuchBerlinGermany

Personalised recommendations